| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
This compound does not possess a specific biological target; its primary function is as a chemical building block for peptide synthesis and photoaffinity labeling. As a phenylalanine derivative with a benzophenone photophore, it is used as a photoactivatable probe for studying biomolecular interactions and mechanisms. The benzophenone moiety serves as a photoactivatable group that, upon exposure to UV light (typically ~350-365 nm), forms covalent crosslinks with nearby C–H bonds, enabling photoaffinity labeling and protein-protein interaction mapping. The compound is fully compatible with automated Fmoc/tBu SPPS.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
This compound is not a biological agent and does not exhibit direct in vitro biological activity in a pharmacological sense. Its value lies in its chemical utility as a protected amino acid building block and photoaffinity probe. Amino acids and amino acid derivatives have been commercially used as ergogenic supplements. Fmoc-D-Bpa-OH can be incorporated into peptide-based drug candidates to enhance stability, receptor binding, or pharmacokinetic properties. Any biological activity would reside in the final peptide product, not in the protected intermediate itself. |
| ln Vivo |
Fmoc-D-Bpa-OH is not administered in vivo as a therapeutic agent. It is a research chemical utilized exclusively as a building block in peptide synthesis and photoaffinity labeling. The final deprotected peptide product, not this protected intermediate, would be the subject of in vivo pharmacological testing for therapeutic efficacy and safety. The compound is designed for biological research and industrial applications, not intended for individual clinical or medical purposes.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays are not applicable to Fmoc-D-Bpa-OH as a drug, but it can be used in photoaffinity labeling studies to map protein-protein interactions. A typical protocol involves incorporating Fmoc-D-Bpa-OH into a peptide via Fmoc SPPS, followed by UV irradiation (350-365 nm) to activate the benzophenone group, which forms covalent crosslinks with nearby molecules. The crosslinked products can then be analyzed by mass spectrometry or other methods to identify interaction partners. The compound achieves 63-70% covalent incorporation efficiency in receptor labeling, outperforming azido and diazirine probes.
|
| Cell Assay |
Fmoc-D-Bpa-OH is not used in cell-based assays as a therapeutic agent. Its applications are in synthetic chemistry and photoaffinity labeling. It is typically stored as a powder at -20°C. It is a solid with a molecular weight of 491.53 g/mol. Purity is typically ≥98% (HPLC). The compound is soluble in common organic solvents such as DMF and DMSO. High purity minimizes deletion sequences, reducing costly peptide re-synthesis and accelerating project timelines.
|
| Animal Protocol |
In vivo animal experiments do not involve Fmoc-D-Bpa-OH as a test article. It is a chemical intermediate used in the synthesis of peptide-based drug candidates or as a tool for studying biomolecular interactions. If a researcher synthesizes a therapeutic peptide using this building block, that final deprotected and purified peptide product would be subjected to animal testing. The Fmoc-protected amino acid itself is never administered to animals as a test compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to Fmoc-D-Bpa-OH as it is not a drug. It is a small molecule (MW 491.53 g/mol) with the formula C31H25NO5. Its properties are relevant for chemical handling and storage rather than for systemic exposure or ADME studies. The Fmoc group is base-labile and designed for synthetic utility, not for bioavailability. The compound is not designed to be bioavailable, as the Fmoc protecting group is intended to be removed during peptide synthesis.
|
| Toxicity/Toxicokinetics |
The toxicity of Fmoc-D-Bpa-OH is not extensively documented, as it is a research chemical not intended for human or veterinary use. As with all Fmoc-protected amino acids, standard laboratory safety precautions should be followed, including handling in a well-ventilated area with appropriate personal protective equipment (gloves, lab coat, safety glasses). The compound should be stored as a powder at -20°C or below and protected from moisture. It is not intended for diagnostic, therapeutic, or other medical applications.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-960.
|
| Additional Infomation |
Fmoc-D-Bpa-OH (Fmoc-D-4-benzoylphenylalanine) is a specialized amino acid derivative utilized primarily in peptide synthesis and photoaffinity labeling. The benzophenone moiety serves as a photoactivatable group that, upon UV exposure, forms covalent crosslinks with nearby C–H bonds. The D-enantiomer configuration provides stereochemical precision for non-natural ligand binding pockets. It achieves 63-70% covalent incorporation efficiency in receptor labeling, outperforming azido and diazirine probes. This compound is not a pharmaceutical and has no clinical trials or approved therapeutic status.
|
| Molecular Formula |
C31H25NO5
|
|---|---|
| Molecular Weight |
491.53
|
| Exact Mass |
491.173
|
| CAS # |
117666-97-4
|
| PubChem CID |
14233361
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
729.0±60.0 °C at 760 mmHg
|
| Flash Point |
394.7±32.9 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.644
|
| LogP |
6.37
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
37
|
| Complexity |
777
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)C[C@H](C(=O)O)NC(=O)OCC3C4=CC=CC=C4C5=CC=CC=C35
|
| InChi Key |
SYOBJKCXNRQOGA-MUUNZHRXSA-N
|
| InChi Code |
InChI=1S/C31H25NO5/c33-29(21-8-2-1-3-9-21)22-16-14-20(15-17-22)18-28(30(34)35)32-31(36)37-19-27-25-12-6-4-10-23(25)24-11-5-7-13-26(24)27/h1-17,27-28H,18-19H2,(H,32,36)(H,34,35)/t28-/m1/s1
|
| Chemical Name |
(2R)-3-(4-benzoylphenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0345 mL | 10.1723 mL | 20.3446 mL | |
| 5 mM | 0.4069 mL | 2.0345 mL | 4.0689 mL | |
| 10 mM | 0.2034 mL | 1.0172 mL | 2.0345 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
